NCT06377930Phase 2Completed

Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

Study sponsor: Rapport Therapeutics Inc. · RAPP

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-09-26Actual
Enrollment · participants30Actual
Source updated2026-02-05Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 28 Jul 2025. After: 26 Sep 2025.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview